Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04966507 · ClinicalTrials.gov registry record · Phase 2

Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention

A Phase 2 study, sponsored by University of California, Los Angeles.

Completed
Registry status
Phase 2
Development phase
89
Enrollment target

NCT04966507 is a Phase 2 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 89 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04966507, a Phase 2 study, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
Phase 2
Development phase
89 participants
Enrollment target

Study Summary

This study aims to determine acceptability and preliminary efficacy of daily use of an antibacterial mouthwash as compared to a placebo mouthwash in reducing the incidence of pharyngeal gonorrhea among a cohort of HIV-positive and high risk HIV-negative men. Investigators plan to test the following hypotheses: 1. Participants will maintain a high level of adherence and satisfaction with daily mouthwash use. Furthermore, the investigators hypothesize that barriers to adherence will include structural factors such as unstable housing and individual level factors such as substance use. 2. Participants receiving the antibacterial mouthwash will have a lower incidence of pharyngeal gonorrhea as compared to participants receiving the placebo mouthwash. Furthermore, the investigators hypothesize that these reductions will remain even after adjusting for other factors such as HIV-status and substance use.

Interventions

  • DRUG Listerine Antiseptic Mouthwash Product
  • DRUG Biotene Mouthwash

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2022-02-17
Est. Completion 2025-12-12
Phase Phase 2

What the Registry Record Tells You About NCT04966507

The ClinicalTrials.gov registry entry for NCT04966507 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Listerine Antiseptic Mouthwash Product is the first listed.

NCT04966507 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04966507 about?

NCT04966507 is a clinical study titled "Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention". This study aims to determine acceptability and preliminary efficacy of daily use of an antibacterial mouthwash as compared to a placebo mouthwash in reducing the incidence of pharyngeal gonorrhea among a cohort of HIV-positive and high risk HIV-negative men. Investigators plan to test the following...

What is the current status of trial NCT04966507?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2022-02-17. Estimated completion is 2025-12-12.

What interventions are being tested in trial NCT04966507?

The interventions under investigation include: Listerine Antiseptic Mouthwash Product (DRUG), Biotene Mouthwash (DRUG).

Who is sponsoring clinical trial NCT04966507?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.